1073558-72-1

Basic information

• Product Name: 8-(6-chloro-1H-benzimidazol-2-yl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one trifluoroacetate
• Synonyms: 8-(6-chloro-1H-benzimidazol-2-yl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one trifluoroacetate
• CAS NO: 1073558-72-1
• Molecular Weight: 496.873
• Mol File: 1073558-72-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 8-(6-chloro-1H-benzimidazol-2-yl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one trifluoroacetate(CAS DataBase Reference)
• NIST Chemistry Reference: 8-(6-chloro-1H-benzimidazol-2-yl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one trifluoroacetate(1073558-72-1)
• EPA Substance Registry System: 8-(6-chloro-1H-benzimidazol-2-yl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one trifluoroacetate(1073558-72-1)

Safety Data

• Hazardous Substances Data: 1073558-72-1(Hazardous Substances Data)

Upstream product

• 1073560-20-9 3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one hydrobromide 
• 76-05-1 trifluoroacetic acid 
• 4887-95-0 2,5-dichloro-1H-benzimidazole 

Relevant articles and documents

BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS

The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts, solvates, stereoisomers thereof, formula (I), R1 may be C1-C4 alkyl, aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; R2 may be halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro; or aryl, heteroaryl or heterocycle, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or R2 may correspond to -0-R3; R3 is a 6-membered aromatic carbocyclic ring which may contain 1 or 2 nitrogen X is carbon or oxygen; Z is carbon or nitrogen; G is a fused 6-membered aromatic carbocyclic ring which may contain 1 or 2 nitrogen; m may be 0 or an integer ranging from 1 to 4; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY- Y5 receptor antagonists.